Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Sarepta Therapeutics
(NQ:
SRPT
)
143.45
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sarepta Therapeutics
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
This Early-Stage Biotech Stock Is Up 400% — Should You Buy Now?
August 19, 2024
Avidity Biosciences' stock has performed incredibly well in 2024. Its Duchenne muscular dystrophy drug is showing strong results in trials.
Via
MarketBeat
How Is The Market Feeling About Sarepta Therapeutics?
August 16, 2024
Via
Benzinga
A Closer Look at 28 Analyst Recommendations For Sarepta Therapeutics
August 15, 2024
Via
Benzinga
$100 Invested In This Stock 10 Years Ago Would Be Worth $600 Today
August 12, 2024
Via
Benzinga
2 Biotech Stocks to Buy Hand Over Fist in August
August 12, 2024
Both of these biotechs are highly innovative companies.
Via
The Motley Fool
Warner Bros, Airbnb And Monster Beverage Are Among Top 10 Large Cap Losers Last Week (Aug 4-Aug 10): Are The Others In Your Portfolio?
August 11, 2024
These 10 stocks had the biggest drop last week, with McKesson Corporation, BIO-TECHNE Corp, and Warner Bros. Discovery, Inc. being the worst performers.
Via
Benzinga
Smart Money Is Betting Big In SRPT Options
August 08, 2024
Via
Benzinga
NASDAQ:SRPT may be ready to breakout.
August 02, 2024
NASDAQ:SRPT may be ready to breakout.
Via
Chartmill
How Avidity Biosciences Just Dropped The Hammer On Sarepta Therapeutics
August 09, 2024
The company is coming up fast with a platform that could take on several of Sarepta's approved treatments.
Via
Investor's Business Daily
McKesson Reports Weak Sales, Joins JFrog, Fastly, Warner Bros. Discovery And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
August 08, 2024
Via
Benzinga
7 Biotech Stocks to Buy for Their Game-Changing Potential
August 08, 2024
Although the market may be reeling from the recent fallout, the red ink presents a viable opportunity in these biotech stocks.
Via
InvestorPlace
Sarepta Therapeutics (SRPT) Q2 2024 Earnings Call Transcript
August 08, 2024
SRPT earnings call for the period ending June 30, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
SRPT Stock Earnings: Sarepta Therapeutics Beats EPS, Misses Revenue for Q2 2024
August 07, 2024
SRPT stock results show that Sarepta Therapeutics beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
Via
InvestorPlace
26 Analysts Have This To Say About Sarepta Therapeutics
July 29, 2024
Via
Benzinga
Here's How Much $1000 Invested In Sarepta Therapeutics 10 Years Ago Would Be Worth Today
July 18, 2024
Via
Benzinga
Here's How Much $100 Invested In Sarepta Therapeutics 10 Years Ago Would Be Worth Today
July 04, 2024
Via
Benzinga
Sarepta Therapeutics Announces Second Quarter 2024 Financial Results and Recent Corporate Developments
August 07, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
3 Genomics Stocks That May Transform Personalized Medicine
August 06, 2024
These are three of the best genomics stocks to buy for a lucrative entry into a specialized section of the biotech industry.
Via
InvestorPlace
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 31, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Therapeutics to Announce Second Quarter 2024 Financial Results
July 29, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Expert Outlook: Sarepta Therapeutics Through The Eyes Of 25 Analysts
July 01, 2024
Via
Benzinga
Looking At Sarepta Therapeutics's Recent Unusual Options Activity
June 26, 2024
Via
Benzinga
SAVA Stock Plunges as Cassava Sciences CEO Steps Down. What to Know.
July 17, 2024
The CEO of Cassava Sciences is stepping down, effective immediately. Here's what this means for troubled SAVA stock.
Via
InvestorPlace
Jim Cramer Says Don't Sell Match Group: 'You've Just Got A Very, Very Smart Investor In There'
July 17, 2024
Jim Cramer doesn't favor Fortinet, but owns Palo Alto Networks for charity. Air Products not doing well due to better run company Linde.
Via
Benzinga
Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives
July 17, 2024
From
Cassava Sciences, Inc.
Via
GlobeNewswire
After a Big Win, Is Sarepta Therapeutics Stock a Buy?
July 06, 2024
One key issue remains unresolved, and it could be a significant one.
Via
The Motley Fool
Has Sarepta Therapeutics Become a No-Brainer Stock Buy After This Recent FDA News?
July 04, 2024
The label expansion paves the way for much more revenue growth for Sarepta in the years ahead.
Via
The Motley Fool
Exposures
Product Safety
1 Soaring Growth Stock to Buy and Hold for 10 Years
July 03, 2024
Let's look beyond the biotech's performance this year.
Via
The Motley Fool
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 28, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Is Pfizer's Pain Sarepta Therapeutics' Gain? Don't Bet on It.
June 26, 2024
One company's negative results can increase scrutiny of another's work.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.